Navigation Links
Avipaxin Is First Entrant in Medical Arsenal for Neuro-Endocrine-Immune Connection(C) Product and Testing Protocols

OSCEOLA, Wis., Aug. 4 /PRNewswire/ -- NeuroScience, Inc. has launched a new product -- Avipaxin -- aimed at decreasing elevated levels of pro-inflammatory cytokines. Avipaxin supports acetylcholine levels by providing substrates for its production and by inhibiting its metabolizing enzyme, acetylcholinesterase. Initial studies at NeuroScience, Inc. revealed a significant decrease in pro-inflammatory cytokines and chemokines after Avipaxin use. These studies also revealed a decrease in the neurotransmitter norepinephrine and an increase in the neurotransmitter serotonin.

Historically, neurotransmitters, cytokines, and hormones were considered signal messengers of the Nervous, Endocrine, and Immune systems, respectively. However, recent evidence shows that those systems are actually part of a single and integrated Neuro-Endocrine-Immune (NEI) Connection(C).

Elevated pro-inflammatory cytokine levels lead to imbalances in neurotransmitter concentrations and raised hormone (cortisol) levels. Neurotransmitters are responsible for people's mood, concentration, sleep, and other mental and emotional functions. Cytokine-induced neurotransmitter imbalances are regularly noticed when people are sad, lethargic, and are unable to focus during an acute viral or bacterial infection. Serotonin, which was increased in the Avipaxin studies, is a particularly important neurotransmitter involved with mood and sleep. Research shows that persistent cytokine elevations lead to numerous physical and emotional symptoms that are difficult to manage.

Avipaxin modulates elevated cytokine levels by supporting acetylcholine-mediated signaling. The cholinergic anti-inflammatory pathway uses the neurotransmitter acetylcholine to down-regulate elevated pro-inflammatory cytokines. Decreasing pro-inflammatory cytokines leads to an indirect normalization of neurotransmitter levels, leading to a positive effect on mood, concentration, sleep, and other emotional and mental processes. Avipaxin should be considered for patients with suspected acute or persistent immune system activation.

Additional information regarding Avipaxin can be found at

About NeuroScience, Inc.:

NeuroScience, Inc, established in 1999, is devoted to medical solutions that improve health by providing novel laboratory assessments and products in the emerging field of NeuroEndocrine Immunology (NEI). The company is research and education-focused and has a database that includes results from over 300,000 patients.

SOURCE NeuroScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology: